HILDEN, Germany & GERMANTOWN, Md. & SHANGHAI--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that its QuantiFERON tuberculosis (TB) testing solution has ...
QIAGEN QGEN recently unveiled its latest offering, the QuantiFERON-EBV RUO (Research Use Only) assay. This addition to the company’s existing QuantiFERON portfolio of tests marks a significant step ...
QIAGEN QGEN recently reached a major landmark in the field of tuberculosis (TB) testing. On World TB Day, the company announced that since the lime of its launch, the company’s QuantiFERON blood test ...
Venlo, the Netherlands, June 15, 2023 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) welcomes the publication of a new, systematic review highlighting the unique value of its ...
QuantiFERON franchise benefits from new applications, products and automation options, building on strengths in tuberculosis detection while addressing new disease targets QuantiFERON SARS-CoV-2 assay ...
QuantiFERON is the leading IGRA blood test. It has established itself as a superior alternative to the tuberculin skin test, which, for example, struggles to accurately identify TB infections in ...
Germantown, Maryland, and Venlo, the Netherlands, June 27, 2024 (GLOBE NEWSWIRE) -- QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it welcomes new guidelines in the United ...
To describe the use of the second-generation QuantiFERON-TB Gold (QFT-G) test in a series of patients in an ophthalmic practice. The charts of all patients who had QFT-G tests ordered by Mayo Clinic ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results